Health Outcomes Data For Wearables Key To Medicare Coverage Expansion

The popularity of wearables for health monitoring is on the rise, with consumers showing a growing interest in devices such as smartwatches, fitness trackers, and smart rings. However, despite this demand, health insurers have been hesitant to reimburse for these devices due to a lack of clinical validation. This could be changing soon, as Medicare is launching an initiative to facilitate access to wearables while collecting data to evaluate health outcomes.

Wearables for health are electronic tools worn on the body that collect, track, and transmit physiological and biometric data. These devices, which often integrate with smartphones and artificial intelligence, are used for preventive care and chronic disease management. While some insurers cover wearables for specific conditions like diabetes or hypertension, coverage is inconsistent, leading many consumers to pay out-of-pocket.

The Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) have introduced initiatives to incorporate wearables and digital health technology into patient healthcare. One such initiative is the ACCESS program, a 10-year pilot project starting soon to improve chronic disease management through technology-supported care.

Under the ACCESS program, CMS will reimburse device companies for wearables and app use for Medicare beneficiaries with chronic conditions like musculoskeletal pain, depression, diabetes, and high blood pressure. However, full payment is contingent on improvements in health outcomes, necessitating comprehensive evidence generation and data reporting.

Continuous Glucose Monitors (CGMs) are a special case of wearable devices that measure glucose levels in interstitial fluid rather than blood. CMS has covered CGMs for certain Medicare patients with diabetes since 2017, citing data that suggests better outcomes for these patients. Under the Biden administration, access to CGMs was expanded in 2023 to include anyone on insulin, eliminating previous blood glucose check requirements.

Companies and patient advocates are now advocating for Medicare to cover CGMs for type 2 diabetes patients who do not use insulin. Recent advancements in diabetes medications may have increased the value of CGMs for this patient population, leading to positive evidence supporting their use.

While wearables are seen as potential game-changers in healthcare, their cost-effectiveness remains uncertain. More research is needed to understand the long-term benefits and strengthen the evidence base for providers, policymakers, and patients. Insurers face immediate financial burdens when purchasing devices, with uncertain returns on investment due to data overload and noise that may not lead to better outcomes.

In conclusion, the evidence base for wearables needs to increase to demonstrate their effectiveness in reducing healthcare costs and improving patient outcomes. Gold standard data from randomized clinical trials showing the impact of wearables on expenditures and hospital admissions would greatly support the integration of these devices into healthcare systems.